Hotgen
Financials
Estimates*
| CNY | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 142m | 187m | 210m | 514m | 5.4b | 3.6b | 541m |
| % growth | - | 32 % | 12 % | 145 % | 945 % | (34 %) | (85 %) |
| EBITDA | 42.0m | 59.0m | 48.0m | 141m | 2.6b | 1.2b | 58.1m |
| % EBITDA margin | 30 % | 32 % | 23 % | 27 % | 49 % | 33 % | 11 % |
| Profit | 30.0m | 48.0m | 34.0m | 112m | 2.2b | 945m | 27.4m |
| % profit margin | 21 % | 26 % | 16 % | 22 % | 41 % | 27 % | 5 % |
| EV / revenue | - | - | 8.5x | 4.0x | 1.0x | 1.2x | 5.7x |
| EV / EBITDA | - | - | 37.3x | 14.5x | 2.0x | 3.5x | 53.1x |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | CNY10.0m | Series A | |
CNY20.0m | Series B | ||
| N/A | N/A | IPO | |
| Total Funding | €3.8m | ||
Recent News about Hotgen
EditHotgen Biotech Co., Ltd. operates in the biotechnology sector, focusing on the development and manufacturing of clinical diagnostic products. The company serves healthcare providers, hospitals, and laboratories by offering advanced diagnostic solutions that aid in the rapid detection of infectious diseases and cancer biomarkers. Hotgen's product lineup includes the MQ60 series and UPT 3A series, which are designed to provide accurate and timely diagnostic results. The company generates revenue through the sale of these diagnostic kits and devices, catering to a growing market demand for efficient and reliable healthcare diagnostics. Hotgen leverages its core technology to maintain a competitive edge in the market, ensuring high-quality and innovative solutions for its clients.
Keywords: biotechnology, clinical diagnostics, infectious diseases, cancer biomarkers, healthcare providers, hospitals, laboratories, diagnostic kits, MQ60 series, UPT 3A series.
